LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for Feb. 19 at Morehouse College in Atlanta. The summit brings together leaders in health, culture, science, and community to advance health equity for Black men and families. Rooted in De La Soul's song "Good Health," written after the passing of founding member David Jolicoeur (Trugoy the Dove), the program reflects the group's evolution from musical pioneers to wellness advocates.
Developed in collaboration with Blacksmith Holdings, the summit will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness. LIXTE stated that the summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA. The company aims to create a space to connect scientific innovation with communities most impacted by health disparities.
LIXTE's lead compound, LB-100, is a PP2A inhibitor that has shown to be well-tolerated in cancer patients at doses associated with anti-cancer activity, according to the company. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. The compound is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm, covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The Good Health Summit represents an intersection of cultural influence and scientific progress, leveraging the legacy of De La Soul to address pressing health issues. By sponsoring this event, LIXTE underscores its commitment to health equity, recognizing that communities of color often bear a disproportionate burden of cancer and other diseases. The summit provides a platform for dialogue between researchers, healthcare providers, and community leaders, aiming to translate scientific advances into tangible benefits for those most affected.
This initiative highlights the importance of partnerships between biotech companies and academic institutions like Morehouse College in fostering community engagement and promoting health literacy. As LIXTE continues to develop LB-100, its involvement in the summit may help raise awareness about clinical trials and encourage participation among underrepresented populations, potentially improving the generalizability of research findings.
For more information on LIXTE and its latest updates, visit the company's newsroom at https://ibn.fm/LIXT. The full press release is available at https://ibn.fm/0kkqK.
